Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/1468
Title: | (-)-Epigallocatechin gallate derivatives for inhibiting proteasome | Authors: | Chan, TH Lam, WH Chow, LMC Dou, QP Kuhn, DJ Kazi, A |
Issue Date: | 9-Jun-2009 | Source: | US Patent 7,544,816 B2. Washington, DC: US Patent and Trademark Office, 2009. | Abstract: | (-)-EGCG, the most abundant catechin, was found to be chemopreventive and anticancer agent. However, (-)-EGCG has at least one limitation: it gives poor bioavailability. This invention provides compounds of generally formula 10, wherein R₁ is selected from the group of --H and C₁ to C[sub 6] acyl group; R₂, R₃, and R₄ are each independently selected from the group of --H, --OH, and C₁ to C[sub 6] acyloxyl group; and at least one of R₂, R₃, or R₄ is --H. The derivatives of (-)-EGCG that is at least as potent as (-)-EGCG. The carboxylate protected forms of (-)-EGCG and its derivatives are found to be more stable than the unprotected forms, which can be used as proteasome inhibitors to reduce tumor cell growth. | Keywords: | Catechin Anticancer agent |
Rights: | Assignee: The Hong Kong Polytechnic University. Assignee: Wayne State University. Assignee: University of South Florida. Assignee: McGill University. |
Appears in Collections: | Patent |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
us7544816b2.pdf | 1.26 MB | Adobe PDF | View/Open |
Page views
103
Last Week
1
1
Last month
Citations as of Apr 14, 2024
Downloads
51
Citations as of Apr 14, 2024
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.